These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study. Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038 [TBL] [Abstract][Full Text] [Related]
12. Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial. Hykin P; Prevost AT; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Hounsome B; Yang Y; Harding SP; Lotery A; Chakravarthy U; Sivaprasad S; JAMA Ophthalmol; 2019 Nov; 137(11):1256-1264. PubMed ID: 31465100 [TBL] [Abstract][Full Text] [Related]
13. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Bahrami B; Hong T; Zhu M; Schlub TE; Chang A Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195 [TBL] [Abstract][Full Text] [Related]
14. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Chang AA; Li H; Broadhead GK; Hong T; Schlub TE; Wijeyakumar W; Zhu M Ophthalmology; 2014 Jan; 121(1):188-192. PubMed ID: 24144450 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U; Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240 [TBL] [Abstract][Full Text] [Related]
16. 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting. Vardarinos A; Gupta N; Janjua R; Iron A; Empeslidis T; Tsaousis KT BMC Ophthalmol; 2017 Apr; 17(1):58. PubMed ID: 28449645 [TBL] [Abstract][Full Text] [Related]
17. Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study. Chan CK; Sarraf D; Abraham P; Lalezary M; Lin SG; Chen X; Nittala MG; Sadda S Am J Ophthalmol Case Rep; 2020 Dec; 20():100916. PubMed ID: 33024885 [TBL] [Abstract][Full Text] [Related]
18. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105 [TBL] [Abstract][Full Text] [Related]
19. Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Chan CK; Jain A; Sadda S; Varshney N Trans Am Ophthalmol Soc; 2014 Jul; 112():160-98. PubMed ID: 25646034 [TBL] [Abstract][Full Text] [Related]
20. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization. Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]